This study is conducted in Asia. The aim of this observational study is to investigate the safety and efficacy of insulin detemir as add-on therapy in type 2 diabetic patients who are using oral antidiabetic drugs.
Study Type
OBSERVATIONAL
Enrollment
2,155
Insulin detemir for s.c. injection, once daily, in addition to current OAD treatment. Dose to be determined by physician.
Novo Nordisk Investigational Site
Kfar Saba, Israel
Novo Nordisk Investigational Site
Amman, Jordan
Novo Nordisk Investigational Site
Amman, Lebanon
Novo Nordisk Investigational Site
Karachi, Pakistan
Change in number of hypoglycaemic events from baseline
Time frame: at 12 and 24 weeks
HbA1c
Time frame: at 12 and 24 weeks
Percentage of subjects to reach HbA1c between 6.5 and 7.0%
Time frame: at 12 and 24 weeks
Glucose variability as measured by FPG
Time frame: at 12 and 24 weeks
Postprandial glycaemic control as measured by PPG
Time frame: at 12 and 24 weeks
Insulin dose and number of injections
Time frame: at 12 and 24 weeks
Body weight
Time frame: at 12 and 24 weeks
Number of adverse drug reactions (ADR)
Time frame: at 12 and 24 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.